ClinicalTrials.gg
TerminatedNCT04634669Updated Jan 28, 2026Results posted

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

A Phase 2 interventional study of AXS-05 (dextromethorphan-bupropion) in Treatment Resistant Depression and Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Terminated at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Axsome Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
This study was terminated once overall program objectives were met.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Enrollment
35th of 181
181 · median 38
Started
2020
with 14 others
Phase 2
52 of 204
8 open now
Registered
116th of 204
by date
Lead sponsor
5 of 204
Axsome Therapeutics, Inc.

Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 35th largest by enrollment of the 181 interventional ones that give a count, is one of 15 that started in 2020, is one of 52 in phase 2, and was the 116th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures

Read the detailed description

Eligible subjects must have either completed Study AXS-05-TRD-201 immediately prior to enrollment in this study or meet the DSM-5 criteria for major depressive disorder (MDD) without psychotic features.

03

Conditions studied

  • Treatment Resistant Depression
  • Major Depressive Disorder

Keywords

  • AXS-05
  • Treatment Resistant Depression
  • TRD
  • NMDA receptor
  • Refractory depression
  • Resistant depression
  • Depression
  • Major depression
  • Dextromethorphan
  • Bupropion
  • MDD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Completed Study AXS-05-TRD-201 OR currently meets the criteria for MDD without psychotic features and with prior antidepressant treatment failure
  • Agree to use adequate method of for the duration of the study
  • Additional criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    AXS-05 (dextromethorphan-bupropion)

    Drug: AXS-05 (dextromethorphan-bupropion)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05

    Time frame: Duration of participation was up to 15 months. TEAEs were defined as any AE with an onset date in the interval between the first study treatment dosing date and 7 days after the last study treatment dosing date.

07

Results

Posted Jan 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneAXS-05
Started181
Completed11
Not completed170
Withdrew: Study terminated by sponsor95
Withdrew: Withdrawal by subject20
Withdrew: All other reasons55

Outcome measures

PrimaryIncidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05
Time frame:
Duration of participation was up to 15 months. TEAEs were defined as any AE with an onset date in the interval between the first study treatment dosing date and 7 days after the last study treatment dosing date.
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05
ParticipantsAXS-05
Subjects with any TEAEs112
Subjects with suspected to be drug-related TEAEs65
Subjects with serious TEAEs7
Subjects with TEAEs that led to drug withdrawal16
Subjects with TEAEs that led to withdrawal from study14
Subjects with TEAEs that resulted in death0

Adverse events

Collected over Duration of participation was up to 15 months. TEAEs were defined as any AE with an onset date in the interval between the first study treatment dosing date and 7 days after the last study treatment dosing date.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AXS-050/181 (0%)7/181 (3.9%)38/181 (21%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAXS-05
Inappropriate antidiuretic hormone secretionEndocrine disorders1/181
CholecystitisHepatobiliary disorders1/181
COVID-19 pneumoniaInfections and infestations1/181
Coronavirus infectionInfections and infestations1/181
Urinary tract infectionInfections and infestations1/181
Procedural painInjury, poisoning and procedural complications1/181
HyponatraemiaMetabolism and nutrition disorders1/181
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/181
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/181
Metabolic encephalopathyNervous system disorders1/181
Most frequent other events
Most frequent other events
EventAXS-05
Covid-19Infections and infestations15/181
NauseaGastrointestinal disorders15/181
HeadacheNervous system disorders12/181

Baseline characteristics

Age, Continuous
Age, Continuous(years)AXS-05
Mean46.6 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)AXS-05
Female113
Male68
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AXS-05
White144
Black or African American29
Asian3
Other3
Multiple2
08

Study locations

20 sites
  • Clinical Research Site
    Little Rock, Arkansas 72209, United States
  • Clinical Research Site
    Redlands, California 92374, United States
  • Clinical Research Site
    Sherman Oaks, California 91403, United States
  • Clinical Research Site
    Upland, California 91786, United States
  • Clinical Research Site
    Miami, Florida 33122, United States
  • Clinical Research Site
    Miami Lakes, Florida 33016, United States
  • Clinical Research Site
    Orlando, Florida 32081, United States
  • Clinical Research Site
    Chicago, Illinois 60634, United States
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
  • Clinical Research Site
    Berlin, New Jersey 08009, United States
  • Clinical Research Site
    Rochester, New York 14618, United States
  • Clinical Research Site
    Staten Island, New York 10312, United States
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
  • Clinical Research Site
    Raleigh, North Carolina 27609, United States
  • Clinical Research Site
    Cincinnati, Ohio 45215, United States
  • Clinical Research Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Site
    Media, Pennsylvania 19063, United States
  • Clinical Research Site
    Dallas, Texas 75243, United States
  • Clinical Research Site
    Friendswood, Texas 77546, United States
  • Clinical Research Site
    Everett, Washington 98201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Feb 2022, 16 months.

Results were first posted in Jan 2026, 3 years 11 months after primary completion. A results delay was requested in Mar 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2020
First posted
Nov 18, 2020
StartActual
Sep 23, 2020
Primary completionActual
Feb 18, 2022
CompletionActual
Mar 4, 2022
Results delay requested
Mar 3, 2023
Results first posted
Jan 28, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04634669
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Sep 23, 2020
Primary completion
Feb 18, 2022
Completion
Mar 4, 2022
Results posted
Jan 28, 2026
Last update
Jan 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion